Regeneron reported Tuesday that its antibody cocktail for coronavirus has show a reduction in overall infections seen within the first week, with 100% prevention of symptomatic infections. CNBC’s Meg Tirrell reports. For access to live and exclusive video from CNBC…
A number of start-ups and major tech companies like Microsoft, Ticketmaster, Apple, and Google are interested in vaccine or immunization passports to help reopen the economy. But public health officials are weary, warning the apps are pointless without more knowledge…
The mutant coronavirus strain in the U.K. is highlighting how we need to invest in genomic sequencing. Dr. Nahid Bhadelia, Infectious Diseases Physician and Director of Special Pathogens at Boston Medical Center, joins Worldwide Exchange with her perspective on how…
The U.S. began vaccinating the population against the coronavirus earlier this month, but mass adoption is not a guarantee. Roughly four in ten Americans say they would “definitely” or “probably” not get a vaccine, according to a recent survey by…
Dr. Rey Panettieri, Rutgers Robert Wood Johnson Medical School professor of medicine, joins ‘Power Lunch’ to discuss Pfizer’s coronavirus vaccine and the concerns some people may have with it. For access to live and exclusive video from CNBC subscribe to…
Ronny Gal, Bernstein senior analyst, joins ‘Closing Bell’ to discuss the timeline for when the U.S. could reach herd immunity on Covid-19 once there is a readily available vaccine. He also talks about the vaccine’s impact on markets. For access…
